Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 4.62
- Piotroski Score 1.00
- Grade Buy
- Symbol (NVCT)
- Company Nuvectis Pharma, Inc.
- Price $7.45
- Changes Percentage (18.07%)
- Change $1.14
- Day Low $6.00
- Day High $7.48
- Year High $12.10
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/06/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.41
- Trailing P/E Ratio -4.5
- Forward P/E Ratio -4.5
- P/E Growth -4.5
- Net Income $-22,260,000
Income Statement
Quarterly
Annual
Latest News of NVCT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Insiders hold 65% of Nuvectis Pharma, Inc. (NASDAQ:NVCT), and they've been buying recently
Nuvectis Pharma's significant insider control indicates vested interests in company growth. Insiders owning 65% of shares show commitment and potential stock price rise. Institutional investors also h...
By Yahoo! Finance | 3 months ago
